Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc., headquartered in Menlo Park, California, is a prominent medical device company dedicated to innovating and commercializing cutting-edge technologies for the treatment of prevalent eye diseases. The company operates through two main segments: Surgical Glaucoma and Dry Eye.
In the Surgical Glaucoma segment, Sight Sciences offers the OMNI Surgical System. This versatile device allows for both canaloplasty and trabeculotomy with a single corneal incision, aimed at reducing intraocular pressure in adults with primary open-angle glaucoma. The efficacy of OMNI has been demonstrated in multiple clinical trials, showing favorable outcomes in lowering intraocular pressure across various stages of glaucoma.
In the Dry Eye segment, the TearCare System is available for ophthalmologists and optometrists. This system helps manage dry eye disease through a single interventional eyelid procedure, providing significant improvements in the signs and symptoms of the condition over time.
Recent clinical trials have highlighted the effectiveness of these devices. For example, the GEMINI Study demonstrated successful results using OMNI combined with cataract surgery, and the SAHARA trial confirmed the benefits of TearCare compared to traditional treatments.
Financially, Sight Sciences derives key revenue from its Surgical Glaucoma segment. The company has seen active customer engagement, as evidenced by the number of OMNI and SION system orders, as well as TearCare SmartLids sales.
For investors and stakeholders, Sight Sciences continues to be a compelling entity with its relentless focus on reimagining eye care through transformative technologies. The company's commitment to improving patient outcomes and expanding its market presence underscores its significance in the ophthalmic medical device industry.
Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for Q1 2022, with total revenue of $14.9 million, marking a 72% increase year-over-year. Surgical Glaucoma revenue rose 70% to $13.9 million, while Dry Eye revenue surged 104% to $1.0 million. The gross profit reached $11.8 million with an 80% gross margin, up from 73% last year. However, operating expenses jumped 89% to $34.0 million, resulting in a net loss of $23.3 million. The company expects full-year 2022 revenue between $67 million and $75 million, reflecting a 37% to 53% growth.
Sight Sciences, a leader in eyecare technology, announced participation in the Bank of America Healthcare Conference scheduled for May 12, 2022, at 9:20 am PT. The event will showcase the company's innovative solutions aimed at enhancing patient care, including the OMNI® Surgical System and TearCare® System, which target prevalent eye diseases. Interested investors can access the live and archived webcast on the company’s Investors page on their website. This initiative underscores the company’s commitment to transforming eyecare.
Sight Sciences, Inc. (Nasdaq: SGHT) announced that data on the OMNI® Surgical System will be presented at the 2022 ASCRS Annual Meeting from April 22-26. The company will also sponsor a MIGS education symposium on April 22. Three posters will be presented, covering outcomes of canaloplasty and trabeculotomy, IOP fluctuations, and combined cataract surgery outcomes in Hispanic patients. Sight Sciences aims to transform eyecare through innovative solutions and is focused on minimally invasive techniques addressing leading causes of eye diseases.
Sight Sciences, Inc. (Nasdaq: SGHT) announced it will report financial results for Q1 2022 on May 10, 2022, after market close. Management will hold a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The company focuses on innovative eyecare solutions like the OMNI® Surgical System and TearCare® System, targeting prevalent eye diseases. Interested investors can access the call through their website or via dial-in options. These systems provide minimally invasive treatments for conditions like glaucoma and dry eye disease.
Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for 2021, achieving $49.0 million in total revenue, a 77% increase from the previous year. Fourth-quarter revenue was $14.7 million, up 63%. Gross margins expanded to 87% compared to 74% in Q4 2020. The company received FDA clearance for the TearCare® System and published significant clinical data supporting the OMNI® Surgical System. Operating expenses surged to $91.8 million in 2021, resulting in a net loss of $63.0 million. Guidance for 2022 projects revenue between $67 million and $75 million.
Sight Sciences (Nasdaq: SGHT) announced the initiation of the TRIDENT clinical trial to examine the OMNI Surgical System as a standalone treatment for lowering intraocular pressure (IOP) in glaucoma patients. This prospective, randomized trial is set to enroll 459 subjects across three study arms and aims to showcase the effectiveness of the next-generation OMNI device compared to the iStent inject. The trial marks a significant advancement in glaucoma management and aims to provide new evidence for treatment options tailored for patients post-cataract surgery.
Sight Sciences (Nasdaq: SGHT) appointed Brenda Becker to its Board of Directors on March 15, 2022. With over 40 years of experience in health policy and legislation, Becker will also serve on the Nominating and Governance Committee. Currently a Senior Vice President at Boston Scientific, her expertise is expected to aid the company in navigating regulatory challenges and enhancing access to innovative eyecare technologies. Becker previously held senior roles in the U.S. government, offering strategic insights crucial for the company's growth in ophthalmology and optometry.
Sight Sciences, Inc. (Nasdaq: SGHT) will report its financial results for the quarter and year ended December 31, 2021, on March 24, 2022, after market close. A conference call to discuss the results will begin at 1:30 PM PT / 4:30 PM ET. The company's innovative solutions, such as the OMNI® and TearCare® systems, focus on improving patient care in eye diseases, including glaucoma and dry eye disease. Investors can access the conference call via webcast or by phone.
Sight Sciences (Nasdaq: SGHT) announced that data from clinical studies of its OMNI® Surgical System will be presented at the 2022 American Glaucoma Society Annual Meeting in Nashville, TN, from March 3-6, 2022. Two posters are set for presentation, focusing on IOP fluctuation suppression and a retrospective analysis of 12-month outcomes in glaucoma treatments. The OMNI® system is a minimally invasive device aimed at reducing intraocular pressure in patients with primary open-angle glaucoma, enhancing treatment paradigms in eyecare.
Sight Sciences (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Citi Virtual Healthcare Conference scheduled for February 23, 2022, at 8:45 am PT. The management will engage in a fireside chat, accessible via a live and archived webcast on the company’s Investors section of its website. Sight Sciences focuses on transforming care standards through minimally invasive technologies, including the OMNI Surgical System for glaucoma and the TearCare System for dry eye treatment.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
What does Sight Sciences, Inc. do?
What products are offered by Sight Sciences in the Surgical Glaucoma segment?
What is the TearCare System?
Where is Sight Sciences, Inc. headquartered?
What were the findings of the GEMINI Study?
How does Sight Sciences contribute to treating dry eye disease?
What financial segment drives Sight Sciences' revenue?
Who can I contact for investor relations at Sight Sciences?
Are there any recent clinical highlights for Sight Sciences?
What trademarks does Sight Sciences hold?
